KR102178967B1 - A Composition for preventing or treating menopausal symptoms comprising fermented Puerariae flos extracts - Google Patents

Abstract

The present invention is a food composition for preventing or improving menopausal symptoms, including a fermented extract of Galhwa (Puerariae flos); Pharmaceutical composition; Quasi-drug composition; A method for preparing the fermented browning extract; And to a method for preventing or improving menopausal symptoms.
The fermented extract of the present invention utilizes strains of the genus Saccharomyces to form glycosides of tectogenin 7-O-xylosylglucoside and/or Tectoridin. ) Is converted into Tectorigenini, which is a non-glycoside, to increase the use in the body, and thus can be usefully used to relieve and ameliorate various menopausal symptoms including facial flushing.

Description

A composition for preventing or treating menopausal symptoms comprising fermented Puerariae flos extracts}

The present invention is a food composition for preventing or improving menopausal symptoms comprising a fermented extract of Galhwa ( Puerariae flos ); Pharmaceutical composition; Quasi-drug composition; A method for preparing the fermented browning extract; And to a method for preventing or improving menopausal symptoms.

The period from menopause to about one year after the onset of menopause is often referred to as the menopausal period, and the period is generally 4 to 7 years on average. According to the Korean Menopause Association, it is known that about 89% of women in their 50s in Korea suffer from menopausal symptoms. Menopause refers to disorders in glucose metabolism, lipid metabolism, bone homeostasis, and energy metabolism, resulting in symptoms of hot flashes, sweating, and atrophy of the genitourinary system in postmenopausal women (vaginitis caused by recurrent vaginal infections and urinary tract infections). , Cystitis, urinary pain, urination), mental instability (concentration and short-term memory impairment, anxiety and nervous irritability, decreased memory), skin joint system changes (skin dryness and atrophy, muscle pain, joint pain), increased fractures due to the progression of osteoporosis Menopausal symptoms, such as an increase in body mass index (BMI), may occur.

It is known that administration of synthetic estrogen hormone preparations can solve some of these menopausal symptoms, but on the other hand, there is a problem with side effects that increase the risk of breast cancer and endometrial cancer. Accordingly, in recent years, interest in phytoestrogen, a plant-derived natural estrogen having similar structure and function to estrogens such as isoflavones, flavonoids, and lignans, is increasing. In addition, as reports that natural compounds such as flavonoids act as selective estrogen receptor modulators are increasing, studies on natural herbs as candidate substances for preventing, improving and treating menopausal disorders are actively conducted, improving female menopausal disorders. A red ginseng composite composition having an effect on (Korean Patent Laid-Open Publication No. 10-2006-0061323) has been developed. However, their efficacy is still unclear.

On the other hand, flavonoid compounds derived from natural products, including phytoestrogens, which are plant estrogens, generally exist in the form of glycosides in nature, and such glycosides can be absorbed and used in the intestine only when they are converted into a non-glycoside form by intestinal microorganisms upon ingestion. However, there are many cases where it is difficult to convert the component into a non-glycoside form after being ingested in a glycoside form due to differences between individuals, health conditions, or abnormal intestinal flora, and there are many restrictions on its use. Accordingly, research and product development for bioconversion of such active ingredients in the form of glycosides into a form capable of absorption are active, and demand for them is also increasing.

Under this background, the present inventors have made diligent efforts to discover a composition that has the effect of improving the use of natural substances-derived active ingredients in the body and alleviating and ameliorating menopausal symptoms, and as a result, fermenting the brown flower extract using the Saccharomyces sp. In this case, the present invention was completed by confirming that the effect of preventing and improving menopausal symptoms is further increased.

One object of the present invention is to provide a food composition for preventing or improving menopausal symptoms, including a fermented extract of Puerariae flos .

Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of menopausal symptoms comprising a fermented browning extract.

Another object of the present invention is to provide a pharmaceutical composition for preventing or improving menopausal symptoms comprising a fermented browning extract.

Another object of the present invention is to provide a quasi-drug composition for preventing or improving menopausal symptoms comprising a fermented browning extract.

Another object of the present invention is (a) inoculating a strain of the genus Saccharomyces to the brown flower extract extracted with an extraction solvent; And (b) fermenting the strain-inoculated brown flower extract at 20 to 40°C for 24 to 100 hours.

This will be described in detail as follows. Meanwhile, each description and embodiment disclosed in the present application may be applied to each other description and embodiment. That is, all combinations of various elements disclosed in the present application belong to the scope of the present application. In addition, it cannot be considered that the scope of the present application is limited by the specific description described below.

One aspect of the present invention for achieving the above object is to provide a food composition for preventing or improving menopausal symptoms, including a fermented extract of Puerariae flos .

In the present invention, when fermenting an extract of the genus Saccharomyces using a strain of the genus Saccharomyces, the present invention relates to Tectorigenin 7-O-xylosylglucoside in the form of a glycoside contained in the brown flower and/or It is based on the technical idea that Tectoridin is converted to Tectorigenini, which is a non-glycoside, so that the use in the body is increased, and thus the effect of preventing and improving menopausal symptoms is further increased, which was first identified by the present inventors. . In particular, in case of fermentation of brown flower extract using Saccharomyces cerevisiae , both tectorigenin 7-O-xylosylglucoside and tectoridine were converted into textorogenin, resulting in high yield. It is significant in that it confirmed that Zenin was obtained. That is, when fermenting the brown flower extract with Saccharomyces cerevisiae, the content of non-glycosides compared to glycosides in the brown flower extract may be dramatically increased, but is not limited thereto.

In the present invention, " Puerariae flos " is a flower of Pueraria thomsonii , a perennial vine herb belonging to the leguminosae , and is also called a brown flower, and is one of the herbal medicines widely used in oriental medicine. Is known. The brown flower may be a bud that does not bloom, and may be purchased commercially, or may be used without limitation, harvested or grown in nature.

In the present invention, "fermentation" refers to decomposing organic matter using enzymes possessed by microorganisms. In the present invention, the extract of brown flower can be fermented using an edible microbial strain, specifically the microorganism is a strain of the genus Saccharomyces , more specifically Saccharomyces cerevisiae , Saccharomyces It may be one or more strains selected from the group consisting of Saccharomyces lactis and Saccharomyces fragilis , and more specifically Saaromyces cerevisiae.

In the present invention, "extract" refers to a liquid component obtained by immersing a target substance in various solvents and then extracting it at room temperature, low temperature, or warming state for a certain period of time, and a resultant product such as a solid component obtained by removing the solvent from the liquid component. it means. In addition, it can be comprehensively interpreted as including all of the resulting diluted solution, a concentrated solution thereof, a dried product obtained by drying the extract, or a preparation thereof, a purified product, and the like.

The extract may be extracted without limitation from natural, hybrid, and variety plants, and may be obtained by extraction using water (purified water), alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. In addition, the method for obtaining the extract is not particularly limited as long as it can obtain a sitting brown flower extract, but specifically, a cold needle extraction method in which the brown flower, dried brown flower, and processed product are immersed in the solvent and extracted at room temperature. , Heat extraction, ultrasonic extraction by applying ultrasonic waves, and reflux extraction using a reflux cooler can be used.

In the present invention, "fermentation extract" not only useful substances produced by fermenting the extract itself, but also a fermentation strain culture medium in which a fermentation strain and a fermentation product coexist, a fermentation product obtained by centrifuging a fermentation strain from the culture medium, and the culture medium A fermented product obtained by filtering a fermentation strain from, a fermented product obtained by sterilizing and filtering a fermentation strain from the culture medium, a dilution solution obtained by diluting the fermentation product, and a dried product obtained by drying the fermentation product may be included.

In the present invention, the fermentation extract may be a fermentation extract obtained by fermenting a puerariae flos extract. Specifically, the fermented fermented extract is Saccharomyces ( Saccharomyces ) genus strain, more specifically Saccharomyces cerevisiae ( Saccharomyces cerevisiae ), Saccharomyces lactis ( Saccharomyces lactis ) and Saccharomyces pra It may be one or more strains selected from the group consisting of Saccharomyces fragilis , more specifically, fermented by Saaromyces cerevisiae. The brown flower fermentation extract of the present invention converts the glycosides in the extract into non-glycosides in a high yield due to the characteristics of the strain of the sp. Can increase.

The fermented extract of the present invention uses tectorigenin 7-O-xylosylglucoside and/or tectoridine as non-glycoside Tectorigenin through microbial fermentation. It may have been converted to further increase the absorption capacity in the body.

In the present invention, "Tektorigenin 7-O-xylosylglucoside" is one of the flavonoid compounds, the molecular formula is C ₂₇ H ₃₀ O ₁₅ , the molecular weight is about 594.5. The structure of tectorigenin 7-O-xylosylglucoside is represented by Formula 1 below.

[Formula 1]

In the present invention, "tektoridine" is one of the isoflavone glycosides, the molecular formula is C ₂₂ H ₂₂ O ₁₁ , the molecular weight is about 462. The structure of tectoridine is represented by Chemical Formula 2 below.

[Formula 2]

“Tectorigenin” is one of the isoflavone derivatives, and exists in a non-glycoside form, and has a molecular formula of C ₁₆ H ₁₂ O ₆ and a molecular weight of about 300. The structure of tectorigenin is represented by Formula 3 below.

[Formula 3]

The tectorigenin 7-O-xylosylglucoside, tectoridin, and tectorigenin are components that exhibit activity by being contained in silver gallium or gallium extract, and may act as natural estrogens derived from plants. However, textorigenin 7-O-xylosylglucoside and tektoridine, excluding tektorigenin, exist in the form of glycosides and are difficult to absorb in the body.The present invention provides a ratio of this through fermentation using a strain of the genus Saccharomyces. By converting it to the glycoside, tektorigenin, it is possible to increase the availability in the body, and further relieve and improve menopausal symptoms.

In an embodiment of the present invention, a total of 16 strains including strains of the genus Saccharomyces were used to ferment the brown flower extract, and the amount of tectorigenin conversion was evaluated in each. As a result, Saccharomyces compared to other strains In the case of using the genus strain, it was confirmed that the conversion rate of tectorigenin was remarkably high, and in particular, tectorigenin 7-O-xylosylglucoside and tectoridine only when the brown flower extract was fermented using Saccharomyces cerevisiae. It was confirmed that all can be converted to tektorigenin.

In the present invention, "menopausal symptoms" collectively refer to symptoms and diseases that appear in women before and after menopause as the secretion of estrogen is reduced due to aging of the ovaries. Also called menopausal disorder, menopausal syndrome or menopausal symptoms. In the present invention, the menopausal symptoms are, for example, facial flushing, sweating, nervousness, depression, dizziness, fatigue, joint pain, muscle pain, headache, chest palpitations, sense of pressure, sweating during sleep, sleep disorders, dry skin, vaginal dryness. , Vaginal atrophy, lower urethral atrophy, vaginitis, cystitis, urinary pain, urination, concentration disorder, memory impairment, anxiety, nervousness, memory loss, skin dryness, joint pain and osteoporosis, etc. , Is not limited thereto.

In one embodiment of the present invention, as a result of evaluating the improvement rate of facial flushing before and after ingestion of the brown flower fermented extract, the fermented extract using the Lactobacillus strain did not show a significant difference from the control group before fermentation, whereas the strain of Saccharomyces sp. It was confirmed that the experimental group fermented using not only the control group but also the experimental group fermented using the Lactobacillus sp. strain showed a remarkably superior improvement of the Cooperman index, especially when using Saccharomyces cerevisiae. Was confirmed.

In the present invention, "prevention" means any action that suppresses or delays menopausal symptoms by ingesting or administering the composition of the present invention.

In the present invention, “improvement” refers to any action in which the symptoms of menopausal symptoms are improved or advantageously changed compared to before administration by ingesting or administering the composition of the present invention.

In the present invention, "treatment" refers to any action that improves or disappears menopausal symptoms or related diseases by ingesting or administering the composition of the present invention.

In one embodiment of the present invention, as a result of evaluating the improvement rate of Cooperman's index when ingesting a browning fermented extract fermented using a strain of the genus Saccharomyces and a strain of genus Lactobacillus, in the case of a fermented extract using a strain of genus Lactobacillus While there was no significant difference from the control group before fermentation, it was confirmed that the experimental group fermented using the Saccharomyces sp. strain showed remarkably superior improvement of the Cooperman index compared to the control group as well as the experimental group fermented using the Lactobacillus strain. , In particular, it was confirmed that Saccharomyces cerevisiae showed the best effect.

In the present invention, “food” includes, for example, various foods, beverages, gums, teas, vitamin complexes, health function (sex) foods, and the like, and includes all foods in the usual sense. The food can be prepared in formulations such as tablets, granules, powders, capsules, liquid solutions, and pills according to a known manufacturing method, and the content of the fermented extract according to the present invention is based on the total weight of the food composition according to the formulation. It can be adjusted to 0.0001% by weight to 100% by weight. The food composition of the present invention is not particularly limited to other ingredients, except for including the fermented browning extract or a compound derived therefrom as an active ingredient, and may contain various conventional flavoring agents or natural carbohydrates as additional ingredients, in addition to It may contain food additives acceptable for food.

In the present invention, the term "food supplementary additive" refers to a component that can be added auxiliary to food, and is added to the manufacture of health functional foods of each formulation, and can be appropriately selected and used by those skilled in the art. Examples of food additives include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavors, coloring agents and fillers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners. , pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, etc. are included, but the types of food additives of the present invention are not limited by the above examples.

The food composition of the present invention may contain health functional (sex) food. The term "health function (sex) food" is the same term as food for special health use (FoSHU), and refers to foods with high medical and medical effects that are processed to effectively display bioregulatory functions in addition to nutrition supply. do. The “function (sex)” refers to obtaining a useful effect for health purposes such as controlling nutrients or physiological effects on the structure and function of the human body. The health functional food of the present invention can be prepared by a method commonly used in the industry, and can be prepared by adding raw materials and ingredients commonly added in the industry when preparing the health functional food. In addition, the formulation of the health functional food may be prepared without limitation as long as it is a formulation recognized as a food. The health functional food composition of the present invention can be prepared in various types of formulations, and unlike general drugs, there are no side effects that may occur when taking the drug for a long time using food as a raw material, and has an advantage of excellent portability.

There is no limitation on the form that the health functional food of the present invention can take, and may include all foods in the usual sense, and may be mixed with terms known in the art such as functional foods. In addition, the health functional food of the present invention can be prepared by mixing suitable other auxiliary ingredients and known additives that may be included in the food according to the choice of a person skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and There are vitamin complexes and the like, and can be prepared by adding to juice, tea, jelly, juice, etc. prepared by using the fermented browning extract according to the present invention as a main component. It also includes foods used as feed for animals.

In addition, the health functional food composition may further include a physiologically acceptable carrier, and the type of the carrier is not particularly limited, and any carrier commonly used in the art may be used. In addition, the health functional food composition may include, without limitation, additional ingredients that are commonly used in food compositions to improve smell, taste, vision, etc., and may be selected according to the type of food and used in an appropriate amount.

Another aspect of the present invention for achieving the above object provides a pharmaceutical composition for the prevention or treatment of menopausal symptoms comprising a fermented browning extract. The browning, extract, fermented extract, menopausal symptoms, prevention and treatment are as described above.

In the present invention, the pharmaceutical composition may be used as a single formulation, and may be prepared and used as a combined formulation including additional drugs known to have the effect of alleviating and ameliorating menopausal symptoms, and formulated using a pharmaceutically acceptable carrier or excipient By doing so, it can be manufactured in a unit dosage form or it can be manufactured by incorporating it into a multi-dose container.

The pharmaceutical composition may be administered in a pharmaceutically effective amount. The "pharmaceutically effective amount" means an amount sufficient to prevent menopausal symptoms or treat related diseases with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type and severity of the subject, age, sex, It can be determined according to the activity of the drug, its sensitivity to the drug, the time of administration, the route of administration and the rate of excretion, the duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field.

Another aspect of the present invention for achieving the above object provides a quasi-drug composition for preventing or improving menopausal symptoms comprising a fermented browning extract. The browning, extract, fermented extract, menopausal symptoms, prevention and treatment are as described above.

In the present invention, the quasi-drug composition may further include a pharmaceutically acceptable carrier, excipient, or diluent, if necessary, in addition to the fermented fermentation extract. The pharmaceutically acceptable carrier, excipient, or diluent is not limited as long as it does not impair the effects of the present invention, for example, fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, fragrances, preservatives, etc. Can include.

The "pharmaceutically acceptable carrier" may mean a carrier, excipient, or diluent that does not irritate an organism and does not inhibit the biological activity and properties of the compound to be injected, and specifically, a non-naturally occuring carrier). The kind of the carrier that can be used in the present invention is not particularly limited, and any carrier commonly used in the art and pharmaceutically acceptable can be used. Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and the like. These may be used alone or in combination of two or more.

The composition including a pharmaceutically acceptable carrier may be in various oral or parenteral formulations. In the case of formulation, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used. Specifically, solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations include at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, It can be prepared by mixing gelatin or the like. Further, in addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, and other excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to water and liquid paraffin, which are commonly used simple diluents. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As a base for suppositories, Witepsol, Macrogol, Tween 61, cacao butter, laurin paper, glycerogelatin, and the like can be used.

In addition, the quasi-drug composition of the present invention may exemplify a disinfectant cleaner, a shower foam, an ointment, a wet tissue, a coating agent, etc., but is not limited thereto, and the method of formulating a quasi-drug, a dosage, a method of use, a component, etc. are known in the technical field. It can be appropriately selected from conventional techniques.

Another aspect of the present invention for achieving the above object is (a) preparing a brown flower extract by extracting brown flower with an extraction solvent; (b) inoculating the extract with a strain of the genus Saccharomyces; And (c) culturing the strain inoculated with the extract for 24 to 100 hours at 20 to 40°C. The brown flower, extract, and ferment extract are as described above.

The strain of the genus Saccharomyces is specifically one selected from the group consisting of Saccharomyces cerevisiae , Saccharomyces lactis , and Saccharomyces fragilis . It may be the above strain, more specifically, Saccharomyces cerevisiae, but is not limited thereto. It is obvious to those skilled in the art that inoculation and cultivation of the strain can be performed using methods and tools known in the art. In the culturing step, the culture temperature may be 20 to 40° C., more specifically 25° C., and the culture time may be 24 to 100 hours, but is not limited thereto.

In the case of preparing a fermented extract of browning fermentation according to the production method of the present invention, tectorigenin 7-O-xylosylglucoside and/or tectoridine in the form of a glycoside through the fermentation process of Saccharomyces sp. It can be converted to tektorigenin to increase the usability in the body, and thus can be usefully used in the manufacture of a composition for alleviation, amelioration or treatment of various menopausal symptoms.

Another aspect of the present invention for achieving the above object provides a method for preventing or improving menopausal symptoms, comprising administering a composition containing a browning fermented extract to an individual other than a human. The browning, extract, fermentation extract, menopausal symptoms, prevention and improvement are as described above.

In the present invention, "administration" means introducing the composition of the present invention to an individual by any suitable method, and the route of administration of the composition reaches the target tissue and any effect such as relief or improvement of menopausal symptoms can be achieved. It can be administered through the usual route. The administration may be intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, or intranasal administration, but is not limited thereto. The composition of the present invention may be administered daily or intermittently, and the number of administrations per day may be administered once or divided into 2 to 3 times. In addition, the composition of the present invention may be used alone or in combination with other drug treatments to relieve and ameliorate menopausal symptoms. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and this can be easily determined by a person skilled in the art.

In the present invention, "individual" includes monkeys, cows, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, mice, rabbits, or guinea pigs, including humans who have or may develop the menopausal symptoms. It means all animals, and by administering the composition of the present invention to an individual, it is possible to effectively prevent, ameliorate or treat menopausal symptoms or diseases related thereto.

The fermented extract of the present invention utilizes strains of the genus Saccharomyces to form glycosides of tectogenin 7-O-xylosylglucoside and/or Tectoridin. ) Is converted into Tectorigenini, which is a non-glycoside, to increase the use in the body, and thus can be usefully used to relieve and ameliorate various menopausal symptoms including facial flushing.

Hereinafter, the present invention will be described in more detail through the following examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

Example 1: Brown flower ( Puerariae flos ) Manufacturing process of fermented extract

About 10 times the amount of alcohol was added to the dried raw material of Puerariae flos , and extracted twice at 68-72°C with 70% alcohol. After filtering the extract, it was concentrated to 20-30 Brix at 45-55° C. 1 atmosphere or less, and then powdered by adding an appropriate amount of dextrin. A saccharide in a liquid matrix containing the Pueraria extract 1 to 10% by weight My process (Saccharomyces) genus Lactobacillus bacteria (Lactobacillus) genus Bacillus (Bacillus) genus and a strain of 16 species, such as Streptococcus (Streptococcus) sp After inoculation, the brown flower extract inoculated with the strain was cultured at 25° C. for 24 hours to prepare a brown flower fermented extract (Experimental Groups 1 to 15).

Example 2: Confirmation of the level of conversion of tectorigenin according to the type of fermentation strain

In each of the fermented extracts prepared in Example 1 above, depending on the type of strain, Tectorigenin 7-O-xylosylglucoside (Tectorigenin 7-O-xylosylglucoside) and/or Tectoridin in the form of a glycoside The degree of conversion to non-glycoside, Tectorigenini, was evaluated. It was set as a control group to which the brown flower extract (1%) that did not go through the fermentation step was added to the MRS medium.

[Table 1]

As a result, as can be seen from Table 1, it was confirmed that the experimental groups 1 to 3 using strains of the genus Saccharomyces exhibited significantly higher tectorigenin conversion compared to other strains. In addition, especially in the case of Experimental Group 1 in which the brown flower extract was fermented using Saccharomyces cerevisiae, both tectorigenin 7-O-xylosylglucoside and tectoridine can be converted to textorgenin in high yield. , It was confirmed that the concentration of the obtained tektorigenin was also remarkably high.

That is, this is when fermenting an extract of the genus Saccharomyces, particularly Saccharomyces cerevisiae, the active ingredient in the form of a glycoside contained in the extract of the brown flower is converted into a non-glycoside form, resulting in a marked increase in concentration. Therefore, it is a result indicating that it will exhibit an excellent effect in preventing or ameliorating menopausal symptoms due to increased use in the body.

Example 3: Confirmation of the improvement rate of menopausal symptoms of the fermentation extract of brown stalk according to the type of fermentation strain

In order to check whether each of the browning fermented extracts prepared in Example 1 actually shows a relief or amelioration effect of menopausal symptoms, the fermented extracts of the experimental groups 1 to 5 were powdered and consumed for 4 weeks by 5 g each, The improvement rate and the improvement rate of hot flashes, a typical menopausal symptom, were evaluated. The improvement rate of menopausal symptoms was calculated as the improvement rate of Cooperman's index before and after ingestion, and the results are shown in Table 2 below. The hot flush score was expressed as the cumulative sum of the intensity×number of hot flushes felt during the day, and the scale of the hot flush intensity was a 4 point scale, with 1 point for “light symptoms”, 2 points for “medium symptoms”, and “severe symptoms” 3 points were given to "and 4 points to "Very severe symptoms". The Cooperman index and the improvement rate of hot flashes were calculated as follows.

Improvement rate (%) = (measured value after intake-measured value before ingestion)/measured value before ingestion *100

[Table 2]

As can be seen from Table 2, the fermented extracts of experimental groups 4 and 5 using Lactobacillus strains did not show a significant difference compared to the control group before fermentation, whereas experimental groups 1 to 3 fermented using the strains of the genus Cychromesus It was confirmed that not only the control group but also the experimental group fermented using Lactobacillus strains showed remarkably superior improvement rate of Cooperman's index and improvement rate of facial flushing. In particular, in the case of Experimental Group 1 using Saccharomyces cerevisiae, in addition to the excellent conversion rate of tektorigenin, the improvement rate of Cooperman's index and the improvement rate of hot flashes were also the highest, indicating that it showed excellent effect in preventing or improving menopausal symptoms. Able to know.

Example 4: Saccharomyces cerevisiae ( Saccharomyces cerevisiae ) To evaluate the conversion level of tectogenin according to the fermentation time

For the fermented extract using the Saccharomyces cerevisiae strain, which was confirmed to show the best conversion rate of tectorigenin and the improvement rate of Cooperman's index through Examples 2 and 3, To evaluate the level of conversion. Specifically, changes in the concentrations of tectorigenin 7-O-xylosylglucoside, tectoridine and tectorigenin according to fermentation time (24, 48, 72 hours) were measured, and the results are shown in Table 3 below.

As a result, it was confirmed that the level of conversion to tectorigenin increased in proportion to the passage of fermentation time in the case of the fermented extract prepared using the strain of Saccharomyces cerevisiae, which is an experimental group. This is a result showing that the content of tectorigenin, which is a non-glycoside, is remarkably increased compared to the brown flower extract, which greatly improves the usability in the body.

[Table 3]

From the above description, those skilled in the art to which the present invention pertains will be able to understand that the present invention can be implemented in other specific forms without changing the technical spirit or essential features thereof. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not limiting. The scope of the present invention should be construed that all changes or modifications derived from the meaning and scope of the claims to be described later rather than the above detailed description, and equivalent concepts thereof, are included in the scope of the present invention.

Claims (18)

Saccharomyces ( Saccharomyces ) containing a fermented brown flower ( Puerariae flos ) fermented extract with a strain of the genus,
The Saccharomyces strain is one or more strains selected from the group consisting of Saccharomyces cerevisiae , Saccharomyces lactis , and Saccharomyces fragilis . That is, a food composition for preventing or improving menopausal symptoms.
delete The food composition according to claim 1, wherein the strain of the genus Saccharomyces is Saccharomyces cerevisiae , preventing or improving menopausal symptoms.
The food composition of claim 1, wherein the fermentation extract is prepared by extraction with a solvent selected from the group consisting of water, alcohol having 1 to 4 carbon atoms, and a mixed solvent thereof.
The food composition of claim 1, wherein the fermented extract is contained in an amount of 1 to 10% by weight (w/w) based on the total weight of the composition.
The method of claim 1, wherein the fermentation extract is tectorigenin 7-O-xylosylglucoside (Tectorigenin 7-O-xylosylglucoside) and/or tectoridine (Tectorigenin) in the fermentation extract The conversion is characterized in that to increase the absorption capacity compared to the brown flower extract, the food composition for preventing or improving menopausal symptoms.
The method of claim 1, wherein the menopausal symptoms are facial flushing, sweating, nervousness, depression, dizziness, fatigue, joint pain, muscle pain, headache, chest palpitations, sense of pressure, sweating during sleep, sleep disorder, dry skin, dry vagina, vaginal For the prevention or improvement of menopausal symptoms, selected from the group consisting of atrophy, lower urethral atrophy, vaginitis, cystitis, urinary pain, urination, concentration disorder, memory impairment, anxiety, nervous irritability, memory loss, dry skin, joint pain and osteoporosis Food composition.
The food composition of claim 1, wherein the menopausal symptoms are hot flashes, preventing or improving menopausal symptoms.
Saccharomyces ( Saccharomyces ) containing a fermented brown flower ( Puerariae flos ) fermented extract with a strain of the genus,
The Saccharomyces strain is one or more strains selected from the group consisting of Saccharomyces cerevisiae , Saccharomyces lactis , and Saccharomyces fragilis . Which is, a pharmaceutical composition for the prevention or treatment of menopausal symptoms.
delete The pharmaceutical composition for preventing or treating menopausal symptoms according to claim 9, wherein the strain of the genus Saccharomyces is Saccharomyces cerevisiae .
The method of claim 9, wherein the fermentation extract is Tectorigenin 7-O-xylosylglucoside (Tectorigenin 7-O-xylosylglucoside) and/or Tectoridin as Tectorigenin. The conversion is characterized in that to increase the absorption capacity compared to the brown flower extract, a pharmaceutical composition for the prevention or treatment of menopausal symptoms.
The method of claim 9, wherein the menopausal symptoms are facial flushing, sweating, nervousness, depression, dizziness, fatigue, joint pain, muscle pain, headache, chest palpitations, sense of pressure, sweating during sleep, sleep disorder, dry skin, dry vagina, vaginal Atrophy, lower urethral atrophy, vaginitis, cystitis, urinary pain, urination, concentration disorder, memory impairment, anxiety, nervous irritability, memory loss, skin dryness, arthralgia and osteoporosis, selected from the group consisting of, preventing or treating menopausal symptoms Composition.
Saccharomyces ( Saccharomyces ) containing a fermented brown flower ( Puerariae flos ) fermented extract with a strain of the genus,
The Saccharomyces strain is one or more strains selected from the group consisting of Saccharomyces cerevisiae , Saccharomyces lactis , and Saccharomyces fragilis . That is, a quasi-drug composition for preventing or improving menopausal symptoms.
(a) inoculating strains of the genus Saccharomyces to the brown flower extract extracted with an extraction solvent; And
(b) fermenting the strain-inoculated brown flower extract at 20 to 40°C for 24 to 100 hours,
The Saccharomyces strain is one or more strains selected from the group consisting of Saccharomyces cerevisiae , Saccharomyces lactis , and Saccharomyces fragilis . That is, the method for producing a fermented extract of browning.
delete The method of claim 15, wherein the strain of the genus Saccharomyces is Saccharomyces cerevisiae .
Comprising the step of administering a composition comprising a fermented extract inoculated with a strain of the genus Saccharomyces to an individual other than a human,
The Saccharomyces strain is one or more strains selected from the group consisting of Saccharomyces cerevisiae , Saccharomyces lactis , and Saccharomyces fragilis . What is, a method for preventing or improving menopausal symptoms.